en   |   it


Mandarin Capital Partners, through its portfolio company Euticals, has acquired Archimica from TowerBrook Capital Partners.

Archimica manufactures Active Pharmaceutical Ingredients ("APIs") and late stage intermediates for the pharmaceutical industry. DVRCAPITAL acted as financial advisor to the buyer | January 2011

DVR Capital is a portrait site only, turn you device!